Metagenomi Beats Expectations in Q3

Metagenomi Incorporated, a genetic medicines company, reported a loss of twenty-four million dollars in their third-quarter results, translating to a loss of fifty-five cents per share. However, this loss was five cents less than the average estimate of sixty cents per share by financial experts. The company also posted eight million dollars in revenue, providing a clearer picture of their financial standing.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.